Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H- pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4496-4510

  Wu, Chien Huang ^a   Hung, Ming Shiu ^a   Song, Jen Shin ^a   Yeh, Teng Kuang ^a   Chou, Ming Chen ^a   Chu, Cheng Ming ^a   Jan, Jiing Jyh ^a   Hsieh, Min Tsang ^a   Tseng, Shi Liang ^a   Chang, Chun Ping ^a   Hsieh, Wan Ping ^a   Lin, Yinchiu ^a   Yeh, Yen Nan ^a   Chung, Wan Ling ^a   Kuo, Chun Wei ^a   Lin, Chin Yu ^a   Shy, Horng Shing ^a   Chao, Yu Sheng ^a   Shia, Kak Shan ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL 1H PYRAZOL 3 YL] 1,5,5 TRIMETHYL 1,5 DIHYDROIMIDAZOL 4 THIONE; BPR 890; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; IMIDAZOLE DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; INVERSE AGONISM; MALE; MOUSE; NONHUMAN; OBESITY; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-OBESITY AGENTS; CELL LINE; DIABETES MELLITUS; DIET; DRUG DISCOVERY; DRUG INVERSE AGONISM; EATING; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, OBESE; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SUBSTRATE SPECIFICITY; THIONES;

EID: 67650714102     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900471u     Document Type: Article

References (35)

1. Howleff, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G. International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors. Pharmacol. Rev. 2002, 54, 161-202.
2. (a) Lange, J. H. M.; Kruse, C. G. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discovery Today 2005, 10, 693-702.
3. (b) Janero, D. R.; Makriyannis, A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin. Emerging Drugs 2009, 14, 43-65.
4. Di Marzo, V. CB1 receptor antagonism: biological basis for metabolic effects. Drug Discovery Today 2008, 13, 1026-1041.
5. Fong, T. M. Development of anti-obesity agents: drugs that target neropeptide and neurotransmitter systems. Expert Opin. Investig. Drugs 2008, 17, 321-325.
6. Carrier, E. J.; Kearn, C. S.; Barkmeier, A. J.; Breese, N. M.; Yang, W.; Nithipatikom, K.; Pfister, S. L.; Campbell, W. B.; Hillard, C. J. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol. 2004, 65, 999-1007.
7. (a) Bays, H.; Dujovne, C. Pharmacotherapy of obesity: currently marketed and upcoming agents. Am. J. Cardiovasc. Drugs 2002, 2, 245-253.
8. (b) Kaya, A. ; Aydin, N.; Topsever, P.; Filiz, M.; Oztürk, A.; Daǧar, A.; Kilinç, E.; Ekmekcioglu, C. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed. Pharmacother. 2004, 58, 582-587.
9. Clark, D. W.; Harrison-Woolrych, M. Sibutramine may be associated with memory impairment. Br. J. Med. 2004, 329, 1316.
10. Rinaldi-Carmona, M.; Barth, F.; Héaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Néliat, G.; Caput, D. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350, 240-244.
11. Lin, L. S.; Lanza, T. J.; Jewell, J. P.; Liu, P.; Shah, S. K.; Qi, H.; Tong, X.; Wang, J.; Xu, S. S.; Fong, T. M.; Shen, C. P.; Lao, J.; Xiao, J. C.; Shearman, L. P.; Stribling, D. S.; Rosko, K.; Strack, A.; Marsh, D. J.; Feng, Y.; Kumar, S.; Samuel, K.; Yin, W.; Van der Ploeg, L. H.; Goulet, M. T.; Hagmann, W. K. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)- 2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl] oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J. Med. Chem. 2006, 49, 7584-7587.
12. Griffith, D. A.; Hadcock, J. R.; Black, S. C.; Iredale, P. A.; Carpino, P. A.; Da Silva-Jardine, P.; Day, R.; DiBrino, J.; Dow, R. L.; Landis, M. S.; , R. E.; Scott, D. O. Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H- purin-6-yl]-4-ethylaminopiperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor Antagonist. J. Med. Chem. 2009, 52, 234-237.
13. (a) Storr, M. A.; Sharkey, K. A. The endocannabinoinoid system and gut-brain signaling. Curr. Opin. Pharmacol. 2007, 7, 575-582.
14. (b) Pagotto, U.; Cervino, C.; Vicennati, V.; Marsicano, G.; Lutz, B.; Pasquali, R. How many sites of action for endocannabinoids to control energy metabolism?. Int. J. Obes. 2006, 30 (1S), S39-S43.
15. LoVerme, J.; Duranti, A.; Tontini, A.; Spadoni, G.; Mor, M.; Rivara, S.; Stella, N.; Xu, C.; Tarzia, G.; Piomelli, D. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body weight gain in mice. Bioorg. Med. Chem. Lett. 2009, 19, 639-643.
16. Mcelroy, J. F.; Chorvat, R. J. Cannabinoid receptor antagonists/ inverse agonists useful for treating obesity. WO patent 2007106721, 2007. Results of the study, entitled "Non-brain penetrant CB1 antagonists from Jerin Discovery show beneficial effects in treating diabetes and obesity," were presented in a plenary session at the 2008 Annual Scientific Meeting of the Obesity Society, indicating that CB1 antagonists developed by the Jenrin Discovery could play a role in the treatment of metabolic disorders while reducing risks of psychiatric adverse effects.
17. Waterbeemd, H. V. D.; Camenisch, G.; Folkers, G.; Chretien, J. R.; Raevsky, O. A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Targeting 1998, 6, 151-165.
18. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships. J. Med. Chem. 2006, 49, 7559-7583.
19. Mahar Doan, K. M.; Humphreys, J. E.; Webster, L. O.; Wring, S. A.; Shampine, L. J.; Serabjit-Singh, C. J.; Adkison, K. K.; Polli, J. W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 2002, 303, 1029-1037.
20. Shia, K. S.; Tai, C. L.; Tsao, J. P.; Hsieh, W. P.; Tseng, S. L.; Chao, Y. S.; Hung, M. S. Pyrazole compounds. WO Patent 2008060771 A2, 2008.
21. Cava, M. P.; Levinson, M. I. Thionation reactions of Lawesson's reagents. Tetrahedron 1985, 41, 5061-5087.
22. Mikami, K; Miyamoto, T; Hatano, M. A highly efficient asymmetric Suzuki-Miyaura coupling reaction catalyzed by cationic chiral palladium(II) complexes. Chem. Commun. 2004, 2082-2083.
23. Lee, S. H.; Seo, H. J.; Lee, S. H.; Jung, M. E.; Park, J H.; Park, J. H.; Yoo, J.; Yun, H.; Na, J.; Kang, S. Y.; Song, K. S.; Kim, M. A.; Chang, C. H.; Kim, J.; Lee, J. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. J. Med. Chem. 2008, 51, 7216-7233.
24. Lee, S. H.; Seo, H. J.; Kim, M. J.; Kang, S. Y.; Song, K. S.; Lee, S. H.; Jung, M. E.; Kim, J.; Lee, J. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands. Bioorg. Med. Chem. Lett. 2009, 19, 1899-1902.
25. Chu, C. M.; Hung, M. S.; Hsieh, M. T.; Kuo, C. W.; Suja, T. D.; Song, J. S.; Chiu, H. H.; Chao, Y. S.; Shia, K. S. Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists. Org. Biomol. Chem. 2008, 6, 3399-3407.
26. Song, K. S.; Kim, M. J.; Seo, H. J.; Lee, S. H.; Jung, M. E.; Kim, S. U.; Kim, J.; Lee, J. Synthesis and structure-activity relationship of novel diarylpyrazole imide analogues as CB1 cannabinoid receptor ligands. Bioorg. Med. Chem. 2009, 17, 3080-3092.
27. Preliminary results showed that upon treatment of the DIO rats with 24 in the 30-day efficacy study, the relative weight loss compared with vehicle was 5.1% and 9.5% for the 0.1 and 0.3 mg/kg groups (po qd), respectively. A full account of this work will be published elsewhere in due course.
28. Fong, T. M.; Guan, X.-M.; Marsh, D. J.; Shen, C.-P.; Stribling, D. S.; Rosko, K. M.; Lao, J.; Yu, H.; Feng, Y.; Xiao, J. C.; Van der Ploeg, L. H. T.; Goulet, M. T.; Hagmann, W. K.; Lin, L. S.; Lanza, T. J., Jr.; Jewell, J. P.; Liu, P.; Shah, S. K.; Qi, H.; Tong, X.; Wang, J.; Xu, S. S.; Francis, B.; Strack, A. M.; MacIntyre, D. E.; Shearman, L. P. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4- Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl) pyridin-2-yl]oxy}propanamide (MK-0364), in rodents. J. Pharmacol. Exp. Ther. 2007, 321, 1013-1022.
29. Felder, C. C.; Joyce, K. E.; Briley, E. M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A. L.; Mitchell, R. L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 1995, 48, 443-450.
30. Frang, H.; Mukkala, V. M.; Syysto, R.; Ollikka, P.; Hurskainen, P.; Scheinin, M.; Hemmila, I. Nonradioactive GTP binding assay to monitor activation of G protein-coupled receptors. Assay Drug Dev. Technol. 2003, 1, 275-280.
31. Muccioli, G. G.; Wouters, J.; Charlier, C.; Scriba, G. K. E.; Pizza, T.; Di Pace, P.; De Martino, P.; Poppitz, W.; Poupaert, J. H.; Lambert, D. M. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/ antagonists. J. Med. Chem. 2006, 49, 872-882.
32. (a) Tseng, S. L; Hung, M. S.; Chang, C. P.; Song, J. S.; Tai, C. L.; Chiu, H. H.; Hsieh, W. P.; Lin, Y.; Chung, W. L.; Kuo, C. W.; Wu, C. H.; Chu, C. M.; Tung, Y. S.; Chao, Y. S.; Shia, K. S. Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists. J. Med. Chem. 2008, 51, 5397-5412.
33. (b) Tai, C. L.; Hung, M. S.; Pawar, V. D.; Tseng, S. L.; Song, J. S.; Hsieh, W. P.; Chiu, H. H.; Wu, H. C.; Hsieh, M. T.; Kuo, C. W.; Hsieh, C. C.; Tsao, J. P.; Chao, Y. S.; Shia, K. S. Design, synthesis, and biological evaluation of novel alkenylthiophenes as potent and selective CB1 cannabinoid receptor antagonists. Org. Biomol. Chem. 2008, 6, 447-450.
34. Colombo, G.; Agabio, R.; Diaz, G.; Lobina, C.; Reali, R.; Gessa, G. L. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci. 1998, 63, 113-117.
35. Trillou, R. C.; Arnone, M.; Delgorge, C.; Gonalons, N.; Keane, P.; Maffrand, J. P.; Soubrie, P. Anti-obesity effect of SR141716A, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284, 345-353.